Selected article for: "ace function and aceis arbs"
Author: Gul, Rukhsana; Uh-Hyun, Kim; Alfadda, Assim A.
Title: Renin angiotensin system at the interface of COVID-19 infection
  • Cord-id: j466shis
  • Document date: 2020_10_18
    • ID: j466shis
    Snippet: Angiotensin-converting enzyme 2 (ACE2) has been recognized as a potential entry receptor for SARS-CoV-2 infection. Binding of SARS-CoV-2 to ACE2 allows engagement with pulmonary epithelial cells and pulmonary infection with the virus. ACE2 is an essential component of renin angiotensin system, and involved in promoting protective effects to counter-regulate angiotensin II (Ang II)-induced pathogenesis. The use of angiotensin receptor blockers (ARBs) and ACE inhibitors (ACEIs) was implicitly nega
    Document: Angiotensin-converting enzyme 2 (ACE2) has been recognized as a potential entry receptor for SARS-CoV-2 infection. Binding of SARS-CoV-2 to ACE2 allows engagement with pulmonary epithelial cells and pulmonary infection with the virus. ACE2 is an essential component of renin angiotensin system, and involved in promoting protective effects to counter-regulate angiotensin II (Ang II)-induced pathogenesis. The use of angiotensin receptor blockers (ARBs) and ACE inhibitors (ACEIs) was implicitly negated during the early phase of COVID-19 pandemic, considering the role of these antihypertensive agents in enhancing ACE2 expression thereby promoting the susceptibility to SARS-CoV-2. However, no clinical data has supported this assumption, but indeed evidence demonstrates that ACEIs and ARBs, besides their cardioprotective effects in COVID-19 patients with cardiovascular diseases, might also be beneficial in acute lung injuries by preserving the ACE2 function and switching the balance from deleterious ACE/Ang II/AT(1) receptor axis towards a protective ACE2/Ang (1–7)/Mas receptor axis.

    Search related documents:
    Co phrase search for related documents
    • ace inhibitor and aceis arbs: 1, 2, 3
    • ace inhibitor and acute lung injury: 1, 2, 3, 4
    • ace inhibitor and acute risk: 1, 2, 3, 4, 5
    • ace inhibitor and lung alveolar: 1
    • ace inhibitor arb and aceis arbs: 1, 2
    • ace inhibitor arb and acute lung injury: 1, 2
    • ace inhibitor arb and acute risk: 1
    • aceis arbs and acute lung injury: 1, 2, 3, 4, 5, 6
    • aceis arbs and acute risk: 1, 2, 3, 4, 5
    • acute lung injury and low expression: 1, 2
    • acute lung injury and lung alveolar: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute risk and low expression: 1, 2
    • acute risk and lung alveolar: 1, 2, 3, 4
    • low expression and lung alveolar: 1, 2, 3
    • low expression and lung alveolar epithelial cell: 1, 2